2018 Clinical Trials Safety Treatment 
The Cannigma
MARCH 7, 2022
What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN. Those enrolled in the study will receive 28 days of treatment and then be assessed by pain-rating scales.
MMJ Recs
NOVEMBER 20, 2023
Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Neurological Disorders: Several cannabinoids show promise in the treatment of neurological disorders, including multiple sclerosis (MS) and Parkinson’s disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
AUGUST 21, 2019
Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. This would answer questions about safety and efficacy, they said. AUTHOR: Mark Taylor.
Cannabis Law Report
JULY 1, 2021
Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. The Project.
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. TIMES (Nov.
Cannabis Law Report
JULY 9, 2021
Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. In May 2018, the federal Right to Try Act (the “Act”) was signed into law. Id ; 21 CFR 312.1-10;
Kind Meds (Cannabis Education Blog)
JANUARY 9, 2019
The first-ever cannabis-based drug with FDA approval is Epidiolex*, a new prescription drug designed to treat severe seizure disorders that do not respond to other treatments. After securing FDA approval in June of 2018, Epidiolex’s manufacturer GW Pharma announced the drug should enter the consumer market by the end of 2018.
Expert insights. Personalized for you.
140 
Let's personalize your content